Medical devices, healthcare technology and the business of care
PMA SUPPLEMENT · P130016/S058

Nucleus Hybrid L24 Cochlear Implant System

Cochlear Americas · Decision date Oct 16, 2025

FDA DECISIONP130016/S058

What did the FDA approve?

FDA records P130016/S058 as a supplement to PMA P130016, with the supplement type “Real-Time Process”. The recorded decision is approval, dated Oct 16, 2025.

FDA approval order statement

Cochlear ECochG Measures v3.0 software module within the Cochlear Clinical Extension Platform, to provide compatibility with devices approved under P970051/S225 (CI1000 Series implants, CP1110 Sound Processor, and CP1110S Surgical Processor) and existing acoustic components used with these new devices, in addition to devices already compatible with v2.0. The name of the software module is also changed from v2.0 Cochlear Research Platform ECochG Software module (within Cochlear Research Platform) to v3.0 Cochlear ECochG Measures module (within Cochlear Clinical Extension Platform).
Regulatory pathway
PMA supplement
Supplement type
Real-Time Process
Clinical specialty
Ear, Nose, Throat
Decision date
Oct 16, 2025
FDA change category
Change Design/Components/Specifications/Material

FDA source record

Regulatory record facts

Identifier
P130016/S058
Regulatory pathway
PMA supplement
Product code
PGQ
Decision code
APPR
Decision date
Oct 16, 2025
Source update
Nov 9, 2026
Original record
Open FDA source record

About this medical device

FDA device category: Cochlear implant with combined electrical stimulation and acoustic amplification.

Product code
PGQ
FDA device class
3

For the original device and its historical approval scope, see PMA P130016. Subsequent supplements may change the device or its indications.

FDA decision timeline

  1. P130016 · Original PMA

    NUCLEUS HYBRID L24 COCHLEAR IMPLANT SYSTEM

  2. P130016/S058 received

    Application receipt date recorded by FDA.

  3. P130016/S058 · FDA decision

    Real-Time Process

  4. P130016/S060 · Related supplement

    Cochlear Hybrid Implant System

  5. P130016/S061 · Related supplement

    Cochlear Hybrid Implant System

Timeline entries are records held by MedtechLedger for P130016. View FDA’s full supplement list.

Related devices and submissions

Same PMA: P130016

Product / regulatory recordCompanyPathwayDecision dateSource
Cochlear AmericasPMA approvalMar 20, 2014FDA
Cochlear AmericasPMA supplementApr 30, 2026FDA
Cochlear AmericasPMA supplementSep 28, 2026FDA

Explore the linked device profile

Regulatory context

A PMA supplement records a change to a device with an existing premarket approval. The supplement’s approval applies to the change described in that submission.

FDA describes the real-time supplement process as a review route for minor changes to a device, including certain design, software, sterilization or labeling changes.

Read our guide to FDA clearance and approval · FDA’s explanation of this pathway

Manufacturer intelligence

Cochlear Americas

Headquarters
Not reported
Brand website
Not reported
FDA applicant address
10350 Park Meadows Dr., Lone Tree, CO, 80124

Sources and methodology

FDA fields and approval-order wording are presented as source information. MedtechLedger explanations are identified separately and describe the scope of the recorded decision. Indications from an original PMA are historical unless confirmed against subsequent labeling and supplements.

How we use FDA records